Pharmaceutical

Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often see high relapse rates, and treatment-related deaths remain high. Researchers now report on a study that could provide better therapeutic options for patients. In the Leukemia study, HCI scientists learned how to inhibit and override the negative activity of this chromosome. The findings could possibly lead to future novel drug treatments. The Philadelphia c...